A Revolutionary Brain Map: Unlocking New Possibilities for Parkinson's Treatment
In a groundbreaking development, scientists from Duke-NUS Medical School, in collaboration with researchers worldwide, have crafted an extensive single-cell map of the developing human brain. This remarkable achievement, unveiled in Singapore on November 3, 2025, offers an unprecedented glimpse into the intricate workings of the brain, capturing nearly every cell type, their unique genetic signatures, and their dynamic interactions.
But here's where it gets controversial: Parkinson's disease, a debilitating neurodegenerative disorder, has long been a complex puzzle for medical professionals. Affecting approximately three in every 1,000 individuals aged 50 and above in Singapore, Parkinson's damages crucial midbrain dopaminergic neurons, which play a vital role in controlling movement and learning through the release of dopamine. Restoring these neurons is a key focus in the quest to alleviate symptoms such as tremors and mobility loss.
To gain deeper insights into the development of these neurons in a laboratory setting, the Duke-NUS team developed BrainSTEM (Brain Single-cell Two tiEr Mapping), a two-step mapping framework. In collaboration with partners like the University of Sydney, they analyzed an impressive 680,000 cells from the fetal brain, creating a comprehensive cellular landscape map.
The second phase of this project focused on the midbrain, pinpointing dopaminergic neurons with exceptional precision. This "comprehensive reference map" serves as a global standard, allowing scientists to evaluate the accuracy of midbrain models against the real human brain.
Dr. Hilary Toh, an MD-PhD candidate from Duke-NUS' Neuroscience & Behavioural Disorders program and one of the study's first authors, emphasized the significance of this data-driven blueprint. "Our approach enables scientists to produce high-yield midbrain dopaminergic neurons that accurately reflect human biology. Grafted cells of this caliber are crucial for enhancing cell therapy efficacy while minimizing side effects, offering a promising path forward for individuals living with Parkinson's disease."
The study, published in Science Advances, revealed an intriguing finding: many methods used to grow midbrain cells also produced unwanted cells from other brain regions. This highlights the need for improved laboratory techniques and data analysis to detect and eliminate these off-target cells.
Dr. John Ouyang, Principal Research Scientist at Duke-NUS' Centre for Computational Biology and a senior author of the study, explained the impact of BrainSTEM: "By mapping the brain at single-cell resolution, BrainSTEM provides the precision needed to identify even subtle off-target cell populations. This wealth of cellular detail forms a critical foundation for AI-driven models, revolutionizing how we categorize patients and design targeted therapies for neurodegenerative diseases."
Assistant Professor Alfred Sun, also a senior author of the paper and part of Duke-NUS' Neuroscience & Behavioural Disorders program, added: "BrainSTEM represents a significant advancement in brain modeling. By offering a rigorous, data-driven approach, it accelerates the development of reliable cell therapies for Parkinson's disease. We're establishing a new standard to ensure that future Parkinson's models accurately reflect human biology."
The team plans to make their brain atlases available as an open-source reference, and the multi-tier mapping process as a ready-to-use package. With BrainSTEM's versatility in sieving out any cell type in the brain, labs worldwide can leverage this framework to deepen their understanding, refine workflows, and accelerate discoveries in neuroscience.
Professor Patrick Tan, Senior Vice-Dean for Research at Duke-NUS, highlighted the impact of this study: "This research redefines the benchmark, establishing multi-tier mapping as essential for capturing intricate cellular details in complex biological systems. By unraveling the human midbrain's development in such detail, we can accelerate Parkinson's research and cell therapy, ultimately improving care and offering hope to those affected by the disease."
This groundbreaking research was supported by various programs, including the USyd-NUS Ignition Grant and the Duke-NUS Parkinson's Research Fund, made possible through a generous donation by The Ida C. Morris Falk Foundation.
Duke-NUS, a leader in medical research and education, is dedicated to enhancing patient care through innovative scientific discoveries. This study is part of their ongoing mission to deepen our understanding of the fundamental mechanisms in the human brain, with a focus on creating new therapeutic approaches, especially for patients with neurological conditions.
About Duke-NUS Medical School
Duke-NUS is Singapore's premier graduate entry medical school, established in 2005 through a strategic partnership between Duke University School of Medicine and the National University of Singapore (NUS). With an innovative curriculum, Duke-NUS nurtures students to become versatile "Clinicians Plus," poised to lead the healthcare and biomedical ecosystem in Singapore and beyond. Known for its groundbreaking research and translational innovation, Duke-NUS has gained international recognition through its five Signature Research Programmes and ten Centers. The impact of its discoveries is amplified through its successful Academic Medicine partnership with Singapore Health Services (SingHealth), the largest healthcare group in Singapore. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, harnessing multidisciplinary research and education to transform medicine and improve lives.
